Phase II proof-of-concept trial of Cladribine
Latest Information Update: 15 Oct 2020
At a glance
- Drugs Cladribine (Primary)
- Indications Myasthenia gravis; Neurological disorders
- Focus Proof of concept; Therapeutic Use
- 15 Oct 2020 New trial record
- 13 Oct 2020 According to a Chord Therapeutics media release, the company announced the closing of a USD16 million Series A financing exclusively from leading healthcare investor Omega Funds which the company intends to use to progress cladribine through phase II proof of concept trial.